Back to results
US 2020/0368182 A1Published application
Toxic aldehyde related diseases and treatment
AssigneeAldeyra Therapeutics, Inc.
InventorsTodd Brady, Scott Young, William A. Kinney, Kenneth J. Mandell
Life of this patent
Estimating the term…
Abstract
The present invention provides for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.
Claims42
1-42. (canceled)
A method of advancing healing following photorefractive keratectomy, comprising:
- administering to an eye of a subject who has undergone photorefractive keratectomy a therapeutically effective amount of a compound of formula (I):
- or a pharmaceutically acceptable salt thereof, wherein,
- X is CH;
- Z is N;
- and Y is C with the —NH2 attached;
- p is 0, 1, 2, or 3;
- each RB is independently a halogen, hydroxyl, carbamoyl, amino, or aryl;
- RA is
- and
- each Qa is independently a C1-C6 straight chain alkyl.
7 more elements
Dependencies are inferred from the claim text.